The first two enlisted authors equally contributed to the work.
Long term cryopreservation in 5% DMSO maintains unchanged CD34+ cells viability and allows satisfactory hematological engraftment after peripheral blood stem cell transplantation
Article first published online: 6 FEB 2013
© 2013 International Society of Blood Transfusion
Volume 105, Issue 1, pages 77–80, July 2013
How to Cite
Abbruzzese, L., Agostini, F., Durante, C., Toffola, R. T., Rupolo, M., Rossi, F. M., Lleshi, A., Zanolin, S., Michieli, M. and Mazzucato, M. (2013), Long term cryopreservation in 5% DMSO maintains unchanged CD34+ cells viability and allows satisfactory hematological engraftment after peripheral blood stem cell transplantation. Vox Sanguinis, 105: 77–80. doi: 10.1111/vox.12012
Sources of research support: Fondi di Ricerca Finalizzata (RF 2009-1550818).
- Issue published online: 25 JUN 2013
- Article first published online: 6 FEB 2013
- Manuscript Accepted: 22 OCT 2012
- Manuscript Revised: 18 OCT 2012
- Manuscript Received: 10 JUL 2012
- 5% DMSO;
- CD34+ viability;
- EVA–teflon double bags;
- long-term cryopreservation
Peripheral blood stem cell cryopreservation is associated with cell damage and decreased viability. We evaluated the impact of up to 10 years of cryopreservation (5% DMSO) on viability of CD34+ cells utilizing graft samples of consecutive patients (2002–2012) with different malignancies who underwent stem cell collection and transplantation. Viability of CD34+ cells from oncohaematological patients measured after 5 weeks (97·2 ± 0·6%) or after 9–10 years of cryopreservation (95·9 ± 0·5%) was unaffected. Haemoglobin, granulocyte and platelet recovery after transplantation of long-term cryopreserved grafts occurred within 8–13 days. CD34+ stem cells can be safely stored up to 9–10 years, without affecting cell viability and clinical effectiveness.